keyword
MENU ▼
Read by QxMD icon Read
search

migraine prophylaxis

keyword
https://www.readbyqxmd.com/read/28808924/a-critical-evaluation-on-moh-current-treatments
#1
REVIEW
Andrea Negro, Martina Curto, Luana Lionetto, Simona Guerzoni, Luigi Alberto Pini, Paolo Martelletti
Migraine is the most frequent neurological disorder observed in clinical practice characterized by moderate to severe pain attacks associated with neurological, gastrointestinal, and dysautonomic symptoms. Each year, 2.5% of patients with episodic migraine develop chronic migraine (CM). CM is characterized by high frequency of the attacks that may result into chronic intake of abortive medications. Nearly, the 70% of CM patients referring to tertiary head centers show acute pain medications overuse that may lead to the development of medication overuse headache (MOH)...
August 15, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28800342/use-of-melatonin-versus-valproic-acid-in-prophylaxis-of-migraine-patients-a-double-blind-randomized-clinical-trial
#2
Mohsen Ebrahimi-Monfared, Mojtaba Sharafkhah, Ali Abdolrazaghnejad, Abolfazl Mohammadbeigi, Fardin Faraji
BACKGROUND: Melatonin is known to be effective in curing migraine. OBJECTIVE: This study aimed to investigate the therapeutic effect of melatonin versus sodium valproate in the prophylaxis of chronic migraine. METHODS: This randomized, double-blind, placebo-controlled clinical trial included patients with chronic migraine who were divided into three equal sized groups, and baseline therapy with nortriptyline (10-25 mg) and propranolol (20-40 mg) was used...
2017: Restorative Neurology and Neuroscience
https://www.readbyqxmd.com/read/28770409/-migraine-prophylaxis-with-trigger-point-therapy-and-lymphatic-drainage-a-pilot-study
#3
Delphine Yedikardachian, Stefan Quasthoff, Anita T Lechner, Albrecht Giuliani, Franz Fazekas
Migraine is a complex, multifactorial, neurovascular disorder of the brain. Patients frequently have pericranial trigger points, but trigger point (TP) therapy for migraine has not yet been adequately studied. In contrast, lymphatic drainage (LD) has been studied in patients with migraine. The multifactorial origin of migraine suggests using a combination of approaches such as TP therapy and lymphatic drainage. The present study evaluated the effectiveness of TP therapy alone and in combination with LD in preventing migraine during treatment period and over an 8‑week period after completion of treatment...
August 2, 2017: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28766236/the-impact-of-onabotulinumtoxina-on-severe-headache-days-preempt-56-week-pooled-analysis
#4
Manjit Matharu, Rashmi Halker, Patricia Pozo-Rosich, Ronald DeGryse, Aubrey Manack Adams, Sheena K Aurora
BACKGROUND: OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic migraine (CM). The objective of this analysis was to determine whether onabotulinumtoxinA has an impact on headache-day severity in patients with CM among those patients who were deemed non-responders based on reduction in the frequency of headache days alone. METHODS: Data from the Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical trial program (a 24-week, 2-treatment cycle, double-blind, randomized, placebo-controlled, parallel-group phase, followed by a 32-week, 3-treatment cycle, open-label phase) were pooled for analysis...
December 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28758415/utilization-and-safety-of-onabotulinumtoxina-for-the-prophylactic-treatment-of-chronic-migraine-from-an-observational-study-in-europe
#5
Manjit Matharu, Julio Pascual, Ingela Nilsson Remahl, Andreas Straube, Arlene Lum, Gudarz Davar, Dawn Odom, Lee Bennett, Christina Proctor, Lia Gutierrez, Elizabeth Andrews, Catherine Johannes
Objective To examine treatment utilization patterns and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in routine clinical practice. Background Clinical trials support onabotulinumtoxinA for the prophylaxis of headache in patients with chronic migraine, but real-world data are limited. Design/methods A prospective, observational, post-authorization study in adult patients with chronic migraine treated with onabotulinumtoxinA. Data were collected at the first study injection and approximately every three months for ≤52 weeks for utilization and ≤64 weeks for safety data, and summarized using descriptive statistics...
January 1, 2017: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/28748680/factors-associated-with-favorable-outcome-of-topiramate-migraine-prophylaxis-in-pediatric-patients
#6
Il Han Yoo, WooJoong Kim, Hunmin Kim, Byung Chan Lim, Hee Hwang, Jong Hee Chae, Jieun Choi, Ki Joong Kim
BACKGROUND AND PURPOSE: There are few studies that have investigated predictive factors related to migraine prophylaxis of which produced inconsistent results. The aim of this study was to identify factors that can predict the treatment response to topiramate prophylaxis in pediatric patients with migraine. METHODS: One hundred and thirteen patients who were older than 7 years and received topiramate for at least 3 months were recruited from the Seoul National University Bundang Hospital outpatient clinic from 2005 to 2014...
July 2017: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/28726049/quarterly-repeat-cycles-of-onabotulinumtoxina-in-chronic-migraine-patients-the-benefits-of-the-prolonged-treatment-on-the-continuous-responders-and-quality-of-life-conversion-rate-in-a-real-life-setting
#7
Antonio Santoro, Andrea Fontana, Anna M Miscio, Michele M Zarrelli, Massimiliano Copetti, Maurizio A Leone
OnabotulinumtoxinA was approved for treatment of chronic migraine (CM) after publication of Phase 3 Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials. However, the PREEMPT trials lasted only up to 1 year. The main aim of our retrospective study was to evaluate whether a prolonged treatment of onabotulinumtoxinA (18 months, six quarterly cycles) will sustain or further improve the efficacy results and the quality of life achieved at 6 and 12 months. Patients were adults with CM with or without overuse of drugs, with at least six regularly repeat onabotulinumtoxinA treatments, administered according to the PREEMPT protocol...
July 19, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/28707585/migraine-neurogenic-inflammation-drug-development-pharmacochemical-aspects
#8
Melinda Lukács, János Tajti, Ferenc Fülöp, József Toldi, Lars Edvinsson, László Vécsei
BACKGROUND: Migraine is a primary headache disorder. Despite numerous studies conducted with the aim to understand the pathophysiology of migraine, several aspects are still unclear. The trigeminovascular system plays a key role. Neurogenic inflammation is presumed to be an important factor in migraine pathophysiology, mediated by the activation of primary neurons, leading to the release of various pro-inflammatory neuropeptides and neurotransmitters such as Calcitonin Gene-Related Peptide (CGRP), substance P (SP), and vasoactive intestinal peptide (VIP)...
July 12, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28701441/topiramate-for-pediatric-migraine-prevention
#9
Teeranai Sakulchit, Garth D Meckler, Ran D Goldman
Question I have several teenagers in my clinic with migraine headache and some of them have frequent episodes that cause considerable interference with daily activity. I would like to offer them prophylactic therapy to reduce the frequency of their migraine episodes. Is topiramate an effective and safe option for adolescents? Answer Both Health Canada and the US Food and Drug Administration have approved the use of topiramate for migraine prevention in adults; however, only the US Food and Drug Administration has approved topiramate for migraine prophylaxis in adolescents 12 to 17 years of age...
July 2017: Canadian Family Physician Médecin de Famille Canadien
https://www.readbyqxmd.com/read/28700539/propranolol-treatment-prevents-chronic-central-sensitization-induced-by-repeated-dural-stimulation
#10
Nelly Boyer, Jérémy Signoret-Genest, Alain Artola, Radhouane Dallel, Lénaïc Monconduit
Migraine is currently conceptualized as a chronic disease with episodic manifestations. In some patients, migraine attack frequency increases, leading to chronic migraine. Daily preventive therapy is initiated to decrease attack frequency. Propranolol, a first-line medication for migraine prophylaxis, reduces attack frequency in nearly 50% of patients receiving it. However, the mechanisms of its antimigraine action are unclear. We examined the effect of daily propranolol treatment (10 mg·kg per os, 8 days) in a rat model of recurrent activation of dural nociceptors (repeated infusion of an inflammatory soup (IS) on the dura through a cannula every 2-3 days)...
July 8, 2017: Pain
https://www.readbyqxmd.com/read/28699493/hallucinations-associated-with-topiramate-therapy-a-case-report-and-review-of-the-literature
#11
Shelby L Register, Orlando L Ruano, Deborah L Sanchez, Glenn Catalano, Maria C Catalano
BACKGROUND: Topiramate is a medication that is approved as both monotherapy and adjunctive treatment of seizure disorder in adults and adolescents. It is also approved for migraine prophylaxis. It has been associated with many side effects, including weight loss and the development of renal stones. It has also been associated with various central nervous system side effects such as dizziness, nervousness, parasthesias, and fatigue. Less commonly, it has been associated with the development of psychotic symptoms such as hallucinations...
July 10, 2017: Current Drug Safety
https://www.readbyqxmd.com/read/28667550/onabotulinumtoxin-a-for-the-management-of-chronic-migraine-in-current-clinical-practice-results-of-a-survey-of-sixty-three-italian-headache-centers
#12
Cristina Tassorelli, Marco Aguggia, Marina De Tommaso, Pierangelo Geppetti, Licia Grazzi, Luigi Alberto Pini, Paola Sarchielli, Gioacchino Tedeschi, Paolo Martelletti, Pietro Cortelli
BACKGROUND: Chronic migraine is a complex clinical condition often undertreated. Onabotulinumtoxin A (OBT-A) was approved in Italy in 2013 for symptom relief in patients with chronic migraine who have failed, or do not tolerate, oral prophylactic treatments. However, the impact of OBT-A in clinical practice remains to be defined. METHODS: To investigate the current management of chronic migraine with OBT-A in clinical practice, a web-based survey was conducted among clinicians working in third-level headache centers across Italy...
December 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28649860/do-racial-ethnic-disparities-exist-in-recommended-migraine-treatments-in-us-ambulatory-care
#13
Larry Charleston Iv, James Francis Burke
Background Racial disparities in migraine have been reported in the US. Migraine in African Americans (AA) is more frequent, more severe, more likely to become chronic and associated with more depression and lower quality of life compared to non-Hispanic Whites (NHW). It is possible that racial differences in prescribing practices contribute to these differences, but little is known about the quality of migraine prescribing patterns in the US or whether racial differences exist. Objective To determine if racial differences in quality of migraine medical prescription care exist...
January 1, 2017: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/28579749/comprehensive-review-of-visual-defects-reported-with-topiramate
#14
REVIEW
Lisa Ford, Jeffrey L Goldberg, Fred Selan, Howard E Greenberg, Yingqi Shi
OBJECTIVE: The objective of this study was to analyze clinical patterns of visual field defects (VFDs) reported with topiramate treatment and assess possible mechanism of action (MOA) for antiepileptic drug (AED) associated VFDs. METHODS: A comprehensive topiramate database review included preclinical data, sponsor's clinical trials database, postmarketing spontaneous reports, and medical literature. All treatment-emergent adverse events (TEAEs) suggestive of retinal dysfunction/damage were summarized...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28566169/transcranial-direct-current-stimulation-over-the-primary-motor-vs-prefrontal-cortex-in-refractory-chronic-migraine-a-pilot-randomized-controlled-trial
#15
Suellen Marinho Andrade, Renata Emanuela Lyra de Brito Aranha, Eliane Araújo de Oliveira, Camila Teresa Ponce Leon de Mendonça, Wanessa Kallyne Nascimento Martins, Nelson Torro Alves, Bernardino Fernández-Calvo
Although transcranial direct current stimulation (tDCS) represents a therapeutic option for the prophylaxis of chronic migraine, the target area for application of the electrical current to the cortex has not yet been well established. Here we sought to determine whether a treatment protocol involving 12 sessions of 2mA, 20min anodal stimulation of the left primary motor (M1) or dorsolateral prefrontal cortex (DLPFC) could offer clinical benefits in the management of pain from migraine. Thirteen participants were assessed before and after treatment, using the Headache Impact Test-6, Visual Analogue Scale and Medical Outcomes Study 36 - Item Short - Form Health Survey...
July 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28562550/tricyclic-antidepressants-for-preventing-migraine-in-adults
#16
REVIEW
Xiao-Min Xu, Yang Liu, Mei-Xue Dong, De-Zhi Zou, You-Dong Wei
BACKGROUND: Migraine, ranked as the 7th-highest specific cause of disability worldwide, has caused an enormous burden on the economy and society. Tricyclic antidepressant (TCA) is one of the most commonly drugs for migraine prevention. However, evidence about the efficacy and tolerability of TCAs in the prophylaxis of migraine in adults is somewhat confusing. METHODS: A computerized literature search of the PubMed, Embase, Cochrane, and Web of Science databases from inception to July 2016 was conducted...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28557171/efficacy-and-feasibility-of-antidepressants-for-the-prevention-of-migraine-in-adults-a-meta-analysis
#17
X-M Xu, C Yang, Y Liu, M-X Dong, D-Z Zou, Y-D Wei
BACKGROUND AND PURPOSE: Migraine has greatly impacted the quality of life for migraineurs and was ranked as the seventh highest specific cause of disability worldwide in 2012. Because of the role of serotonin in migraine mechanisms, antidepressants have been used in the prevention of migraine. However, the role of antidepressants for migraine prophylaxis in adults has not been completely established. Our aim was systematically to assess the efficacy and feasibility of antidepressants for the prevention of migraine in adults based on currently available literature...
August 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28551531/transcranial-direct-current-stimulation-tdcs-and-its-influence-on-analgesics-effectiveness-in-patients-suffering-from-migraine-headache
#18
Anna Przeklasa-Muszyńska, Magdalena Kocot-Kępska, Jan Dobrogowski, Maciej Wiatr, Joanna Mika
BACKGROUND: Headache is one of the most common conditions troubling nearly 45% of the world's population. Migraine headache itself, being more common among women, affects 7-18% of people. As much as 20-30% of the population report accompanying aura and neurological symptoms. In many cases, migraine headache can be effectively treated with suitably selected pharmacotherapies which include drugs used in symptomatic treatment. Frequent occurrence of the condition is treated with prophylaxis, which often fails...
March 1, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28548676/the-diagnosis-and-management-of-chronic-migraine-in-primary-care
#19
Werner J Becker
BACKGROUND: Chronic migraine is common, affecting approximately 1% of the general population, and causes significant disability. OBJECTIVE: To summarize optimal involvement of primary care physicians in chronic migraine care, and to provide algorithms to assist them in the diagnosis and management of patients with chronic migraine. METHODS: An analysis of diagnostic and treatment needs in chronic migraine, based on a synthesis of the medical literature and clinical experience...
May 26, 2017: Headache
https://www.readbyqxmd.com/read/28527085/the-use-of-nutraceutics-in-children-s-and-adolescent-s-headache
#20
R Sangermani, A Boncimino
Nutraceutics are the most used non-pharmacological remedies for migraine's prophylaxis in children and adolescents. Doctors interested in use of nutraceuticals for a complete treatment of children's headache should be adequately informed on this treatments' efficacy and safety. Actually there is a lack of official guidelines about use of nutraceuticals in migraine's prevention in children and adolescent and there are few studies with limited efficacy evidences. The most used nutraceuticals for adolescent's and children's headache prophylaxis are: magnesium, coenzyme Q10, riboflavin, butterbur, feverfew and melatonin...
May 2017: Neurological Sciences
keyword
keyword
111314
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"